Hatteras Venture Partners

LifeFlow rapid fluid infusion devices

Biotech developing inhaled therapies that target mucus obstruction in chronic lung disease. Spun out of UCSF.

Intestinal tissue models for drug development

Gene therapy for inherited retinal diseases

AI-driven climate-resilient crop development using machine learning

Conditionally active biologics for oncology

Digital mental health and addiction treatment platform

Virtual clinic for managing cancer treatment side effects

Advanced multi-omic biomarker measurement tools for personalized health

Vascular embolic protection devices

Medical-device company developing point-of-care hemostasis diagnostics, including a Viscoelastic Coagulation Monitor.

Oncology therapeutics development

Precision-oncology diagnostics company applying gene-expression biology to liquid-biopsy sequencing through its ExpressCT fragmentomics platform and biomarker services.

RNA-based biological products for agriculture

Selective CDK2 inhibitor developer advancing INX-315 for CDK4/6-resistant ER+/HER2- breast cancer and CCNE1-amplified solid tumors.

Small-molecule inhibitors targeting obesity and metabolic disorders

AI-powered cell manufacturing platform for human cell production

Medical devices for vascular access

Drug formulation technology with microglassification delivery systems

Clinical biopharmaceutical company focused on chronic kidney disease

Implantable synthetic lymph node for CAR-T cell generation

Genome editing with ARCUS nuclease technology

Small molecule drug discovery platform targeting RNA structures

AAV gene therapy vectors

AI platform for cancer drug discovery

Medical device company developing surgical tools for cardiothoracic disease

Epigenome editing therapeutics for chronic diseases